Status:
COMPLETED
A Trial Of SU14813 In Patients With Advanced Solid Malignancies
Lead Sponsor:
Pfizer
Conditions:
Neoplasms
Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to define the Maximum tolerated dose of SU14813 when administered as single agent in patients with solid tumors.
Eligibility Criteria
Inclusion
- Patients with a histologically proven advanced solid malignancy for which no recognized therapy was available or for which standard therapy had failed
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Serum albumin ≥3.0 g/dL and adequate haemopoietic, renal and liver function
Exclusion
- Chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy or an investigational agent within 4 weeks before the start of study treatment
- Subjects had to have recovered from all prior treatment toxicities, except alopecia, and from any major surgery.
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT00982267
Start Date
December 1 2003
End Date
June 1 2011
Last Update
August 8 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Hamburg, Germany, 20246
2
Pfizer Investigational Site
Amsterdam, Netherlands, 1081 HV